Find a Doctor
scrolled:
screen width:
window width:

studies

Continuous subcutaneous insulin infusion therapy

The benefits of continuous subcutaneous insulin infusion (CSII) therapy have been demonstrated through years of research. Recent research on OmniPod® has demonstrated important findings on accuracy of insulin delivery and improvement in glycemic control.


Siphon Effects of Continuous Subcutaneous Insulin Infusion Pump Delivery Performance

Journal of Diabetes Science and Technology, 2010
This study demonstrated that changing the position of a conventional continuous subcutaneous insulin infusion (CSII) pump in relation to the insulin infusion site results in significant fluctuations in insulin delivery especially during low bolus rates.There was significantly less variability in insulin delivery with OmniPod® compared to pumps using tubing.

From Journal of Diabetes Science and Technology, Vol. 4, 2010; 98-103
Reprinted with permission from Diabetes Technology Society.



Clinical Experience with a Tubing-Free Insulin Pump System

Infusystems USA, 2009
A retrospective, 1-year study of clinical experience with the OmniPod® System in patients with both type 1 and type 2 diabetes showed that the OmniPod® System demonstrated improvements in glycemic control with OmniPod® in patients previously on multiple daily injections (MDI).

From Infusystems USA, Vol. 6, 2009; 25-27
Reprinted with permission from Infusystems USA.



Quantifying the Impact of a Short-Interval Interruption of Insulin-Pump Infusion Sets on Glycemic Excursions

Diabetes Care, 2008
A prospective, open-label study demonstrated that even short-term interruption of insulin delivery can cause blood glucose levels to rise and remain elevated for hours post-interruption.

From Infusystems USA, Vol. 6, 2009; 25-27
Reprinted with permission from Infusystems USA.



Insulin Pump Therapy: A meta-analysis

Diabetes Care, 2003
Examining the metabolic and psychosocial impact of insulin pump therapy, this study concluded that insulin pumps improve glycemic control as compared with other therapies.

From Diabetes Care®, Vol. 26, 2003; 1079-1087
Reprinted with permission from The American Diabetes Association.



Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Regimens Using Insulin Lispro in Type 1 Diabetic Patients on Intensified Treatment

Diabetes Care, 2000
A randomized study compared the efficacy of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI). Subjects using CSII achieved much better glycemic control using less insulin than subjects using MDI.

From Diabetes Care®, Vol. 23, 2000; 1232-1235
Reprinted with permission from The American Diabetes Association.



Reduction in Severe Hypoglycemia With Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes

Diabetes Care, 1996
This study compared the incidence of severe hypoglycemia in patients who switched to continuous subcutaneous insulin infusion (CSII) from multiple daily injections (MDI). It concluded that CSII therapy produced a "marked and sustained reduction" in hypoglycemia, due to the reproducible and flexible insulin delivery.

From Diabetes Care®, Vol. 19, 1996; 324-327
Reprinted with permission from The American Diabetes Association.

These clinical studies were all performed with the OmniPod® System PDM model UST200.